197 related articles for article (PubMed ID: 37108231)
1. Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma.
Chang HS; Kim Y; Lee SY; Yun HJ; Chang HJ; Park KC
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108231
[TBL] [Abstract][Full Text] [Related]
2. Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer.
Kim Y; Yun HJ; Choi KH; Kim CW; Lee JH; Weicker R; Kim SM; Park KC
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003602
[TBL] [Abstract][Full Text] [Related]
3. Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma.
Kim SM; Park K; Lim JH; Yun HJ; Kim SY; Choi KH; Kim CW; Lee JH; Weicker R; Pan CH; Park KC
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142303
[TBL] [Abstract][Full Text] [Related]
4. Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer.
Yun HJ; Kim M; Kim SY; Fang S; Kim Y; Chang HS; Chang HJ; Park KC
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054884
[TBL] [Abstract][Full Text] [Related]
5. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
6. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
7. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract][Full Text] [Related]
9. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
[No Abstract] [Full Text] [Related]
10. A sorafenib-sparing effect in the treatment of thyroid carcinoma cells attained by co-treatment with a novel isoflavone derivative and 1,25 dihydroxyvitamin D3.
Izkhakov E; Sharon O; Knoll E; Aizic A; Fliss DM; Kohen F; Stern N; Somjen D
J Steroid Biochem Mol Biol; 2018 Sep; 182():81-86. PubMed ID: 29702263
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Mortensen ACL; Berglund H; Hariri M; Papalanis E; Malmberg C; Spiegelberg D
Sci Rep; 2023 Oct; 13(1):16844. PubMed ID: 37803074
[TBL] [Abstract][Full Text] [Related]
12. Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy.
Xie W; Zeng Y; Hu L; Hao J; Chen Y; Yun X; Lin Q; Li H
Front Immunol; 2022; 13():991656. PubMed ID: 36211409
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
[TBL] [Abstract][Full Text] [Related]
14. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
Henderson YC; Ahn SH; Kang Y; Clayman GL
Clin Cancer Res; 2008 Aug; 14(15):4908-4914. PubMed ID: 18676765
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of sorafenib in metastatic thyroid cancer.
Kloos RT; Ringel MD; Knopp MV; Hall NC; King M; Stevens R; Liang J; Wakely PE; Vasko VV; Saji M; Rittenberry J; Wei L; Arbogast D; Collamore M; Wright JJ; Grever M; Shah MH
J Clin Oncol; 2009 Apr; 27(10):1675-84. PubMed ID: 19255327
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
19. Papillary thyroid cancer organoids harboring BRAF
Chen D; Su X; Zhu L; Jia H; Han B; Chen H; Liang Q; Hu C; Yang H; Liu L; Li P; Wei W; Zhao Y
J Transl Med; 2023 Jan; 21(1):9. PubMed ID: 36624452
[TBL] [Abstract][Full Text] [Related]
20. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Lin SF; Lin JD; Yeh CN; Huang YT; Chou TC; Wong RJ
Endocr Relat Cancer; 2019 Aug; 26(8):727-738. PubMed ID: 31189135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
